Adverse event identification and management in locally advanced/metastatic urothelial carcinoma

touchPANEL DISCUSSION for touchONCOLOGY

Listen to an oncologist, urologist and nurse discuss adverse event identification and management with immunotherapies and targeted therapies for locally advanced or metastatic urothelial carcinoma. 

The experts:

• Dr Axel Merseburger, University Hospital Schleswig-Holstein, Campus Lübeck, Germany
• Dr André Fay, PUCRS School of Medicine, Porto Alegre, Brazil
• Ms Maria Lapuente, St Bartholomew’s Hospital, London, UK
  

This touchPODCAST is for HCPs outside the US only. 

This activity is funded by an independent medical education grant from Astellas Inc. and Seagen Inc., and is jointly provided by USF Health and touchIME.

For further information please visit: https://touchoncologyime.org/adverse-event-identification-and-management-in-locally-advanced-metastatic-urothelial-carcinoma